CIK 0001048477 · Large accelerated filer
BIOMARIN PHARMACEUTICAL INC
Sign in to watch- Ticker
- BMRN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 680397820
- Phone
- 4155066700
- Business address
- 105 DIGITAL DRIVE, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,163,748
- in 1 filing
Net −$1,163,748. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-10 | BIENAIME JEAN JACQUES Director | Option exercise 10b5-1 | +20,000 | $63.10 | $1.3M | 494,994 |
| 2024-05-10 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −20,000 | $81.14 | $1.6M | 474,994 |
| 2024-05-10 | BIENAIME JEAN JACQUES Director | Option exercise · Stock Option (Right to Buy Common Stock) 10b5-1 | −20,000 | 51,000 | ||
| 2024-05-09 | BIENAIME JEAN JACQUES Director | Option exercise 10b5-1 | +20,000 | $63.10 | $1.3M | 494,994 |
| 2024-05-09 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −20,000 | $81.62 | $1.6M | 474,994 |
| 2024-05-09 | BIENAIME JEAN JACQUES Director | Option exercise · Stock Option (Right to Buy Common Stock) 10b5-1 | −20,000 | 71,000 | ||
| 2024-05-03 | Guyer Charles Greg EVP, Chief Technical Officer | Shares withheld for taxes | −4,440 | $82.44 | $366K | 74,132 |
| 2024-05-02 | Davis George Eric EVP, Chief Legal Officer | Option exercise 10b5-1 | +1,850 | $63.10 | $117K | 58,007 |
| 2024-05-02 | Davis George Eric EVP, Chief Legal Officer | Sale 10b5-1 | −1,850 | $85.01 | $157K | 56,157 |
| 2024-05-02 | Davis George Eric EVP, Chief Legal Officer | Option exercise · Stock Option (Right to Buy Common Stock) 10b5-1 | −1,850 | 40,850 | ||
| 2024-05-02 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Sale 10b5-1 | −5,000 | $82.91 | $415K | 66,767 |
| 2024-04-30 | FUCHS HENRY J President, Worldwide R&D | Grant or award | +300 | $68.65 | $21K | 197,172 |
| 2024-04-30 | Mueller Brian EVP, Chief Financial Officer | Grant or award 10b5-1 | +300 | $68.65 | $21K | 72,159 |
| 2024-04-30 | Guyer Charles Greg EVP, Chief Technical Officer | Grant or award | +245 | $68.65 | $17K | 78,572 |
| 2024-04-30 | Davis George Eric EVP, Chief Legal Officer | Grant or award 10b5-1 | +301 | $68.65 | $21K | 56,157 |
| 2024-04-30 | Ajer Jeffrey Robert EVP, Chief Commercial Officer | Grant or award 10b5-1 | +300 | $68.65 | $21K | 71,767 |
| 2024-04-12 | BIENAIME JEAN JACQUES Director | Option exercise 10b5-1 | +20,000 | $63.10 | $1.3M | 494,994 |
| 2024-04-12 | BIENAIME JEAN JACQUES Director | Sale 10b5-1 | −20,000 | $91.26 | $1.8M | 474,994 |
| 2024-04-12 | BIENAIME JEAN JACQUES Director | Option exercise · Stock Option (Right to Buy Common Stock) 10b5-1 | −20,000 | 91,000 | ||
| 2024-04-11 | BIENAIME JEAN JACQUES Director | Option exercise 10b5-1 | +20,000 | $63.10 | $1.3M | 494,994 |
Page 8 of 10 · 187 trades